SLC35A2 and Hyperbilirubinemia: Since atazanavir inhibits the uridine diphosphate glucuronosyltransferase (UGT), responsible for bilirubin conjugation, patients living with HIV with the UGT1A1*28 allele present a high risk of hyperbilirubinemia (15, 30).